EGFR and neoplasm: The antitumour efficacy of bispecific antibodies plus talazoparib was not improved in the tumours that were insensitive to EGFR blockade, corresponding to the high expression of VIM and FN1 genes and relatively low expression of CDH1 and CLDN7 genes (Figure 5C).